Key regions: Brazil, India, Australia, United States, United Kingdom
Antiviral drugs have been a crucial part of the healthcare sector in Uganda, just as in many other countries. As the world grapples with the COVID-19 pandemic, the demand for antiviral drugs has surged, and Uganda is no exception.
Customer preferences: In Uganda, the demand for antiviral drugs has been primarily driven by the prevalence of viral infections such as HIV/AIDS, hepatitis B, and C. These infections have been a major public health concern in the country, and antiviral drugs are the first line of treatment for them. Additionally, the COVID-19 pandemic has further increased the demand for antiviral drugs in the country.
Trends in the market: The antiviral drugs market in Uganda has been growing steadily over the years. The market has been driven by the increasing prevalence of viral infections, as well as the growing demand for antiviral drugs. The market has also been fueled by the increasing investments in the healthcare sector, which has led to the development of new and innovative antiviral drugs.
Local special circumstances: The healthcare sector in Uganda faces several challenges, including a shortage of healthcare professionals, inadequate infrastructure, and limited access to healthcare services in rural areas. These challenges have impacted the availability and affordability of antiviral drugs in the country. However, the government has taken several measures to address these challenges, including increasing funding for the healthcare sector and expanding access to healthcare services in rural areas.
Underlying macroeconomic factors: The antiviral drugs market in Uganda is influenced by several macroeconomic factors, including the country's GDP growth, inflation rates, and foreign exchange rates. The country's GDP growth has been steady over the years, which has led to increased investments in the healthcare sector. However, inflation rates have been high, which has impacted the affordability of antiviral drugs. Additionally, the depreciation of the Ugandan shilling has led to an increase in the cost of imported antiviral drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
